• Consensus Rating: Buy
  • Consensus Price Target: $48.75
  • Forecasted Upside: 71.78%
  • Number of Analysts: 17
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 17 Buy Ratings
  • 0 Strong Buy Ratings
$28.38
▲ +1.06 (3.88%)

This chart shows the closing price for IMVT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Immunovant Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IMVT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IMVT

Analyst Price Target is $48.75
▲ +71.78% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for Immunovant in the last 3 months. The average price target is $48.75, with a high forecast of $57.00 and a low forecast of $34.00. The average price target represents a 71.78% upside from the last price of $28.38.

This chart shows the closing price for IMVT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 17 polled investment analysts is to buy stock in Immunovant. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/1/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2023
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/26/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/25/2024
  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/24/2024

Latest Recommendations

  • 0 strong buy ratings
  • 17 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/18/2024Cantor FitzgeraldReiterated RatingOverweightLow
6/3/2024OppenheimerLower TargetOutperform ➝ Outperform$50.00 ➝ $46.00Low
5/30/2024Cantor FitzgeraldReiterated RatingOverweightLow
5/30/2024HC WainwrightReiterated RatingBuy ➝ Buy$51.00 ➝ $51.00Low
3/28/2024OppenheimerInitiated CoverageOutperform$50.00Low
3/25/2024Truist FinancialReiterated RatingBuy ➝ Buy$48.00Low
3/13/2024The Goldman Sachs GroupInitiated CoverageBuy$50.00Low
2/20/2024JPMorgan Chase & Co.Initiated CoverageOverweight$51.00Low
2/15/2024Wolfe ResearchInitiated CoverageOutperform$55.00Low
1/12/2024Cantor FitzgeraldReiterated RatingOverweightLow
12/21/2023Bank of AmericaBoost TargetBuy ➝ Buy$49.00 ➝ $51.00Low
12/21/2023HC WainwrightBoost TargetBuy ➝ Buy$47.00 ➝ $51.00Low
12/12/2023Deutsche Bank AktiengesellschaftInitiated CoverageBuy$50.00Low
12/1/2023UBS GroupBoost TargetBuy ➝ Buy$55.00 ➝ $56.00Low
11/15/2023Truist FinancialBoost TargetBuy ➝ Buy$30.00 ➝ $48.00Low
10/24/2023Piper SandlerBoost TargetOverweight ➝ Overweight$28.00 ➝ $57.00Low
10/24/2023HC WainwrightBoost TargetBuy ➝ Buy$29.00 ➝ $47.00Low
10/16/2023Cantor FitzgeraldBoost TargetOverweight ➝ Overweight$30.00 ➝ $45.00Low
10/13/2023UBS GroupUpgradeNeutral ➝ Buy$18.00 ➝ $55.00Low
10/9/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00Low
9/27/2023GuggenheimBoost Target$32.00 ➝ $48.00Low
9/27/2023CitigroupBoost TargetBuy ➝ Buy$33.00 ➝ $50.00Low
9/27/2023Wells Fargo & CompanyBoost TargetOverweight ➝ Overweight$33.00 ➝ $48.00Low
9/26/2023Truist FinancialReiterated RatingBuy ➝ Buy$30.00Low
9/26/2023Raymond JamesUpgradeMarket Perform ➝ Outperform$40.00Low
9/22/2023GuggenheimReiterated RatingBuy ➝ Buy$32.00Low
9/18/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00Low
8/22/2023Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$30.00Low
8/16/2023Truist FinancialReiterated RatingBuy ➝ Buy$30.00Low
8/11/2023HC WainwrightReiterated RatingBuy ➝ Buy$29.00Low
8/11/2023CitigroupBoost TargetBuy ➝ Buy$28.00 ➝ $33.00Low
7/24/2023Wells Fargo & CompanyBoost TargetOverweight$27.00 ➝ $33.00Low
7/18/2023Stifel NicolausBoost TargetBuy$28.00 ➝ $34.00Low
7/18/2023HC WainwrightBoost TargetBuy$27.00 ➝ $29.00Low
7/10/2023Chardan CapitalReiterated RatingBuyLow
5/23/2023Bank of AmericaBoost Target$26.00 ➝ $28.00Low
5/23/2023GuggenheimBoost Target$30.00 ➝ $32.00Low
5/23/2023HC WainwrightBoost Target$26.00 ➝ $27.00Low
5/22/2023Chardan CapitalBoost Target$21.00 ➝ $32.00Low
5/1/2023Bank of AmericaInitiated CoverageBuy$26.00Low
4/25/2023CitigroupInitiated CoverageBuy$28.00Low
3/31/2023Piper SandlerInitiated CoverageOverweight$28.00Low
3/29/2023Stifel NicolausInitiated CoverageBuy$28.00Low
3/20/2023HC WainwrightBoost Target$21.00 ➝ $26.00Low
2/15/2023Cantor FitzgeraldInitiated CoverageOverweight$30.00Low
2/13/2023GuggenheimUpgradeNeutral ➝ Buy$30.00Low
2/7/2023HC WainwrightBoost TargetBuy$17.00 ➝ $21.00Low
2/6/2023SVB LeerinkBoost TargetOutperform$14.00 ➝ $21.00Low
2/5/2023Chardan CapitalBoost TargetBuy$19.00 ➝ $21.00Low
1/2/2023Wells Fargo & CompanyUpgradeEqual Weight ➝ Overweight$10.00 ➝ $27.00Low
11/17/2022Truist FinancialBoost Target$30.00Low
11/8/2022Wells Fargo & CompanyBoost TargetEqual Weight$7.00 ➝ $10.00Low
11/7/2022HC WainwrightBoost TargetBuy$16.00 ➝ $17.00Low
11/7/2022Chardan CapitalBoost TargetBuy$12.00 ➝ $19.00Low
11/4/2022SVB LeerinkBoost TargetOutperform$12.00 ➝ $14.00Low
9/29/2022Chardan CapitalLower TargetBuy$14.00 ➝ $12.00Low
9/26/2022UBS GroupDowngradeBuy ➝ Neutral$7.00 ➝ $5.00Low
6/9/2022Robert W. BairdLower Target$6.00High
6/9/2022HC WainwrightReiterated RatingBuy$16.00High
5/20/2022UBS GroupLower Target$7.00High
3/30/2022Chardan CapitalLower Target$20.00 ➝ $14.00High
3/29/2022Chardan CapitalReiterated RatingBuyMedium
3/22/2022Chardan CapitalReiterated RatingBuyLow
2/7/2022HC WainwrightReiterated RatingBuy$16.00Low
1/5/2022Chardan CapitalLower TargetBuy ➝ Buy$22.00 ➝ $20.00High
12/30/2021Truist FinancialReiterated RatingBuy$12.00N/A
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$9.00Low
11/8/2021HC WainwrightLower TargetBuy$19.00 ➝ $16.00Low
10/26/2021Truist FinancialLower TargetBuy$24.00 ➝ $12.00High
8/13/2021Chardan CapitalLower TargetBuy$55.00 ➝ $22.00High
8/10/2021HC WainwrightReiterated RatingBuy$19.00Low
8/3/2021Robert W. BairdDowngradeOutperform ➝ Neutral$20.00 ➝ $10.00High
8/2/2021Credit Suisse GroupDowngradeNeutral ➝ Underperform$12.00 ➝ $7.00High
7/7/2021Chardan CapitalReiterated RatingBuyLow
7/1/2021Chardan CapitalReiterated RatingBuyMedium
6/2/2021Credit Suisse GroupBoost TargetNeutral$12.00 ➝ $26.00Low
6/2/2021SVB LeerinkLower TargetOutperform$38.00 ➝ $17.00Medium
6/2/2021Robert W. BairdLower TargetOutperform$32.00 ➝ $20.00High
6/2/2021HC WainwrightLower TargetBuy$23.00 ➝ $19.00High
6/1/2021Raymond JamesDowngradeOutperform ➝ Market PerformHigh
6/1/2021GuggenheimDowngradeBuy ➝ NeutralHigh
6/1/2021Stifel NicolausDowngradeBuy ➝ Hold$28.00 ➝ $9.00High
5/10/2021HC WainwrightLower TargetBuy$33.00 ➝ $23.00High
2/16/2021Stifel NicolausReiterated RatingBuy$28.00Low
2/3/2021Raymond JamesLower TargetOutperform$58.00 ➝ $35.00Medium
2/3/2021SVB LeerinkLower TargetOutperform$52.00 ➝ $38.00High
2/3/2021HC WainwrightLower TargetBuy$54.00 ➝ $33.00High
2/2/2021Credit Suisse GroupDowngradeOutperform ➝ NeutralHigh
2/2/2021Stifel NicolausLower TargetBuy$54.00 ➝ $33.00Low
1/13/2021HC WainwrightReiterated RatingBuy$54.00High
11/13/2020Truist FinancialBoost Target$52.00 ➝ $62.00Medium
11/13/2020Robert W. BairdBoost TargetOutperform$47.00 ➝ $64.00Medium
11/13/2020HC WainwrightBoost TargetBuy$40.00 ➝ $54.00High
11/13/2020SVB LeerinkBoost TargetOutperform$39.00 ➝ $52.00High
11/12/2020Chardan CapitalBoost Target$45.00 ➝ $60.00High
10/28/2020UBS GroupInitiated CoverageBuy$61.00Medium
10/12/2020GuggenheimInitiated CoverageBuy$63.00Medium
10/7/2020Stifel NicolausInitiated CoverageBuy$46.00Medium
10/6/2020Lifesci CapitalReiterated RatingOutperformHigh
10/2/2020CSFBInitiated CoverageOutperform$49.00High
10/2/2020Credit Suisse GroupInitiated CoverageOutperform$49.00High
8/26/2020Truist FinancialBoost Target$36.00 ➝ $52.00Low
8/26/2020HC WainwrightReiterated RatingBuy$34.00 ➝ $40.00High
8/25/2020Robert W. BairdBoost TargetOutperform$31.00 ➝ $47.00Medium
8/25/2020Chardan CapitalBoost TargetPositive ➝ Buy$35.00 ➝ $45.00Medium
8/24/2020Raymond JamesInitiated CoverageOutperform$35.00High
8/20/2020SVB LeerinkBoost TargetOutperform ➝ Outperform$26.00 ➝ $34.00Medium
8/13/2020Chardan CapitalBoost TargetBuy$30.00 ➝ $35.00High
8/5/2020Ci CapitalReiterated RatingBuy$32.00Medium
7/29/2020HC WainwrightInitiated CoverageBuy$34.00Medium
6/18/2020SunTrust BanksUpgradeBuyHigh
6/17/2020SunTrust BanksBoost Target$24.00 ➝ $36.00Low
5/29/2020NomuraBoost TargetBuy$27.00 ➝ $37.00High
5/29/2020Nomura InstinetBoost TargetBuy$27.00 ➝ $37.00High
3/4/2020Nomura SecuritiesReiterated RatingBuy$27.00Medium
2/24/2020SVB LeerinkInitiated CoverageOutperform$24.00High
2/17/2020Chardan CapitalReiterated RatingBuyMedium
2/4/2020Nomura SecuritiesInitiated CoverageBuy$27.00High
1/10/2020SunTrust BanksInitiated CoverageBuy$24.00High
1/9/2020Chardan CapitalInitiated CoverageBuy$30.00High
1/7/2020Robert W. BairdInitiated CoverageOutperform$21.00Medium
(Data available from 6/24/2019 forward)

News Sentiment Rating

1.15 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/27/2023
  • 18 very positive mentions
  • 13 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
12/27/2023
  • 10 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/26/2024
  • 18 very positive mentions
  • 14 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
2/25/2024
  • 14 very positive mentions
  • 15 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/26/2024
  • 13 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/25/2024
  • 10 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/25/2024
  • 17 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/24/2024

Current Sentiment

  • 17 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Immunovant logo
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia. The company is headquartered in New York, New York. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
Read More

Today's Range

Now: $28.38
Low: $27.38
High: $28.44

50 Day Range

MA: $28.11
Low: $25.10
High: $31.48

52 Week Range

Now: $28.38
Low: $18.16
High: $45.58

Volume

223,846 shs

Average Volume

1,206,953 shs

Market Capitalization

$4.14 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.67

Frequently Asked Questions

What sell-side analysts currently cover shares of Immunovant?

The following equities research analysts have issued research reports on Immunovant in the last twelve months: Bank of America Co., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, HC Wainwright, JPMorgan Chase & Co., Oppenheimer Holdings Inc., Piper Sandler, Raymond James, Stifel Nicolaus, The Goldman Sachs Group, Inc., Truist Financial Co., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for IMVT.

What is the current price target for Immunovant?

16 Wall Street analysts have set twelve-month price targets for Immunovant in the last year. Their average twelve-month price target is $48.75, suggesting a possible upside of 73.8%. Piper Sandler has the highest price target set, predicting IMVT will reach $57.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $34.00 for Immunovant in the next year.
View the latest price targets for IMVT.

What is the current consensus analyst rating for Immunovant?

Immunovant currently has 17 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe IMVT will outperform the market and that investors should add to their positions of Immunovant.
View the latest ratings for IMVT.

What other companies compete with Immunovant?

How do I contact Immunovant's investor relations team?

Immunovant's physical mailing address is 320 WEST 37TH STREET, NEW YORK NY, 10018. The company's listed phone number is 917-580-3099 and its investor relations email address is [email protected]. The official website for Immunovant is www.immunovant.com. Learn More about contacing Immunovant investor relations.